2929 7TH STREET, SUITE 105, BERKELEY, CA
Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Reports First Quarter 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results and Provides Business Update
Caribou Biosciences Reports Positive ANTLER Trial Results for Vispa-cel (CB-010)
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
Correspondence
Submission Upload